CA2953459A1 - Markers and therapeutic indicators for glioblastoma multiforme (gbm) - Google Patents

Markers and therapeutic indicators for glioblastoma multiforme (gbm) Download PDF

Info

Publication number
CA2953459A1
CA2953459A1 CA2953459A CA2953459A CA2953459A1 CA 2953459 A1 CA2953459 A1 CA 2953459A1 CA 2953459 A CA2953459 A CA 2953459A CA 2953459 A CA2953459 A CA 2953459A CA 2953459 A1 CA2953459 A1 CA 2953459A1
Authority
CA
Canada
Prior art keywords
gbm
proteins
level
tissue
hmox1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953459A
Other languages
English (en)
French (fr)
Inventor
Dhimankrishna GHOSH
Charles S. Cobbs
Nathan D. Price
Leroy Hood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Publication of CA2953459A1 publication Critical patent/CA2953459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2953459A 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm) Abandoned CA2953459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017748P 2014-06-26 2014-06-26
US62/017,748 2014-06-26
PCT/US2015/038043 WO2015200823A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Publications (1)

Publication Number Publication Date
CA2953459A1 true CA2953459A1 (en) 2015-12-30

Family

ID=54938849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953459A Abandoned CA2953459A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Country Status (6)

Country Link
US (1) US20170176439A1 (enExample)
EP (1) EP3161489A4 (enExample)
JP (1) JP2017522555A (enExample)
AU (1) AU2015279660A1 (enExample)
CA (1) CA2953459A1 (enExample)
WO (1) WO2015200823A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177982A1 (en) 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours
CN107653319B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物circ8:61680968|61684188及应用
JP7211604B2 (ja) * 2017-12-05 2023-01-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
CN108956997A (zh) * 2017-12-29 2018-12-07 广西壮族自治区人民医院 Cd151蛋白表达量elisa检测方法及试剂盒
CN110211634B (zh) * 2018-02-05 2022-04-05 深圳华大基因科技服务有限公司 一种多组学数据联合分析的方法
AU2019361781A1 (en) * 2018-10-14 2021-06-03 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers
CN114267447B (zh) * 2021-09-26 2025-05-06 吴安华 一种预测胶质母细胞瘤免疫微环境、预后及治疗敏感性的基因集及系统和方法
PL446389A1 (pl) * 2023-10-15 2025-04-22 Warszawski Uniwersytet Medyczny Nowe markery do diagnozowania glejaka wielopostaciowego oraz ich zastosowania

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006122519A (ru) * 2003-12-24 2008-01-27 Сайос, Инк. (Us) Лечение злокачественных глиом ингибиторами тфр-бэта
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2679943A1 (en) * 2007-03-02 2008-09-12 Board Of Regents, The University Of Texas System Multigene assay to predict outcome in an individual with glioblastoma
EP2377952A1 (en) * 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
US20120207753A1 (en) * 2009-08-21 2012-08-16 Centre Hospitalier Universitaire Vaudois Methods of using cd44 fusion proteins to treat cancer
US8404437B2 (en) * 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer

Also Published As

Publication number Publication date
EP3161489A1 (en) 2017-05-03
WO2015200823A1 (en) 2015-12-30
JP2017522555A (ja) 2017-08-10
US20170176439A1 (en) 2017-06-22
AU2015279660A1 (en) 2017-01-19
EP3161489A4 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
CA2953459A1 (en) Markers and therapeutic indicators for glioblastoma multiforme (gbm)
Taavitsainen et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Wadsworth et al. Identification of patients with head and neck cancer using serum protein profiles
US9746481B2 (en) Biomarkers of brain injury
Zhou et al. Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue
CN113025713A (zh) 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
Häggmark et al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis
US9140687B2 (en) Renal cell carcinoma biomarkers
Portier et al. HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma
Liang et al. Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes
US20230047712A1 (en) Methods of Treatments Based Upon Molecular Response to Treatment
KR101384211B1 (ko) 췌장암 진단용 마커 및 이의 용도
EP2605017A1 (de) Markersequenzen für gynäkologisches Malignom und deren Verwendung
KR101390590B1 (ko) 췌장암 재발 예후 예측용 마커 및 이의 용도
US20140242608A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
US11714089B2 (en) Combination of markers for diagnosing cancer
WO2024020427A2 (en) Methods for the detection and treatment of ovarian cancer
US20210080465A1 (en) SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia
WO2020198299A1 (en) Compositions and methods for characterizing and treating alzheimer's disease
WO2021129976A1 (en) Method for diagnosing cutaneous t-cell lymphoma diseases
US20250271439A1 (en) Proteomic signature of plasma extracellular vesicles classifies response to doxorubicin and cancer
US10288619B2 (en) Biomarkers for human monocyte myeloid-derived suppresor cells
Shao et al. 443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy
Gach et al. Opioid-receptor gene expression and localization in cancer cells
Brown et al. Theme 06-TISSUE BIOMARKERS.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831